IMDX Reports Q1 2026 Results and Update on GraftAssure Commercialization

Insight Molecular Diagnostics Inc. reported growing customer demand for its kidney transplant monitoring assay, GraftAssureDx, seeking FDA authorization for commercialization. The company highlights its new affordable and faster testing capabilities that can be performed in-house at local transplant labs, aiming to capture a $2 billion market opportunity. Recent pilot programs have shown positive developments and the presentation of independent research data at international conferences supports the efficacy of their technology compared to competitors.